Twist Bioscience

Twist Bioscience reported positive financial results for the fiscal first and second quarters of 2024. The company launched several new products, including multiplexed gene fragments for high-throughput screening applications, synthetic RNA control for H5N1 Influenza A, IVDR-compliant Precision Dx Products for whole exome sequencing, and CHO Express Antibodies. Additionally, Twist Bioscience expanded its Express Genes Rapid Synthesis Service and published preclinical data on an antibody targeting an emerging checkpoint inhibitor. The company also announced a collaboration with Element Biosciences on exome sequencing solutions for the AVITI System and the clinical progression of Pure Biologics’ antibody candidate discovered using Twist’s antibody libraries. Despite a recent market value decrease, shareholders experienced a 132% increase over the past year.

Twist Bioscience is advancing synthetic DNA solutions through seamless nucleic acid assembly, as described in 'Methods for seamless nucleic acid assembly.' They are also innovating in oligonucleotide synthesis with tethered nucleotides, enhancing enzymatic polynucleotide synthesis. Their research includes variant nucleic acid libraries, such as those for SIRPα antibodies, and parallel substrates for biomolecule processing, which improve multiplexing capabilities. These efforts highlight Twist Bioscience's focus on efficient DNA synthesis, variant library creation, and advanced biomolecule processing.